Niemann-Pick Type C
The latest sourced reporting on Niemann-Pick Type C from Dementias Today: dated, and plain about what the evidence does and does not show.
The published record behind the adrabetadex application is a conference abstract reporting a 71 per cent lower risk of death against matched external controls, not a randomised trial. Hearing loss remains the known harm.
A US early access programme for Niemann-Pick disease type C, registered as NCT04316637, has produced four-year outcomes in 109 participants at 14 sites, 53 of them adults. Severity scores were reported as broadly stable, but nobody in the programme received a comparison treatment.
The CHMP found the efficacy evidence insufficient on 23 July 2026, two years after the same drug was approved in the United States. Zevra has asked for re-examination and is keeping its expanded access programme open.